UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000023509
Receipt number R000027079
Scientific Title Effects of Kihito on cognitive functions in Alzheimer's disease patients
Date of disclosure of the study information 2016/08/22
Last modified on 2018/09/18 17:47:54

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of Kihito on cognitive functions in Alzheimer's disease patients

Acronym

Effects of Kihito on cognitive functions in Alzheimer's disease patients

Scientific Title

Effects of Kihito on cognitive functions in Alzheimer's disease patients

Scientific Title:Acronym

Effects of Kihito on cognitive functions in Alzheimer's disease patients

Region

Japan


Condition

Condition

Alzheimer's disease

Classification by specialty

Neurology Psychosomatic Internal Medicine Geriatrics
Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Investigation of cognitive functions at pre and post (16 weeks after) administration of Kampo medicine, Kihito.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

At the pre and post (for 16 weeks) administration of kKihito, these tests of cognitive functions are done; Mini Mental State Examination (MMSE)and Repeatable Battery for the Assessment (RBANS).

Key secondary outcomes

analysis of the blood


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Only Cholinesterase inhibitor (aricept, for 16 weeks - Cholinesterase inhibitor plus Kihito for 16 weeks
*without washout period
*Tsumura Kihito (2.5 g in package; 3 packages/day)

Interventions/Control_2

Cholinesterase inhibitor plus Kihito for 16 weeks - Only Cholinesterase inhibitor (aricept, for 16 weeks
*without washout period
*Tsumura Kihito (2.5 g in package; 3 packages/day)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

Adults living in Toyama prefecture, who was diagnosed as Alzheimer's disease by cognitive testa and image analyses, and has taken any cholinesterase inhibitor more than 6 months. Score of MMSE in the person is above 15 points.

Key exclusion criteria

Persons whose MMSE score is below 14 points.

Target sample size

24


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Chihiro Tohda

Organization

University of Toyama

Division name

Division of Neuromedical Science, Institute of Natural Medicine

Zip code


Address

2630 Sugitani, Toyama, 930-0194, JAPAN

TEL

076-434-7646

Email

chihiro@inm.u-toyama.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Chihiro Tohda

Organization

University of Toyama

Division name

Division of Neuromedical Science, Institute of Natural Medicine

Zip code


Address

2630 Sugitani, Toyama, 930-0194, JAPAN

TEL

076-434-7646

Homepage URL


Email

chihiro@inm.u-toyama.ac.jp


Sponsor or person

Institute

University of Toyama

Institute

Department

Personal name



Funding Source

Organization

University of Toyama

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立大学法人 富山大学


Other administrative information

Date of disclosure of the study information

2016 Year 08 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2016 Year 03 Month 07 Day

Date of IRB


Anticipated trial start date

2016 Year 08 Month 22 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry

2018 Year 09 Month 30 Day

Date trial data considered complete

2018 Year 12 Month 31 Day

Date analysis concluded

2019 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2016 Year 08 Month 05 Day

Last modified on

2018 Year 09 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027079


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name